CluePoints, a provider of Risk-Based Monitoring (RBM) solutions for clinical trials, has announced three new appointments to its global team. John Colby and Elizabeth Polvent join the company's U.S business development team, fulfilling a key element in its strategy for growth, while CluePoints also welcomes Jean Stéphenne, president of the board of directors of GlaxoSmithKline Biologicals, as a member of its board.

Colby joins CluePoints as senior director of business development on the East Coast U.S., providing strategic leadership and driving business growth in the geography. Previously of Aptiv Solutions and PRA International, Colby brings a strong track record of managing strategic relationships in the clinical trials industry.

Polvent has been named as the company's director of business development on the West Coast. Based in California, she has more than 10 years' clinical operations experience in the industry with her most recent roles as the key liaison on Federally funded clinical trials, as well as overseeing early-phase clinical development programs. She joins CluePoints to support the growth of the business' footprint and to establish long-term partnerships with key customers in the region.

Stéphenne joined SmithKline-RIT (now GSK Biologicals) in 1974 as head of bacterial and viral vaccines production. Through various executive management positions within the company, he has led GSK's global vaccines business since 1988. Jean currently is a special advisor to the CEO at GSK, is a member of the corporate executive team (GSK Group), as well as president of the board of directors of GSK Biologicals.